Market Overview

UPDATE: Piper Jaffray Initiates Inovio Pharmaceuticals at Overweight on DNA Vaccine Outlook

Share:
Related INO
Morning Market Losers
Benzinga's Top #PreMarket Losers
Inovio Pharma teams up with GeneOne to develop MERS vaccine (Seeking Alpha)

Piper Jaffray initiated coverage on Inovio Pharmaceuticals (NYSE: INO) with an Overweight rating and a $1.00 price target.

Piper Jaffray noted, "Inovio is developing a novel DNA-based vaccine platform, utilizing proprietary electroporation technology to create robust immune responses. Inovio's vaccines have demonstrated provocative immune responses in early studies against a multiple non-viral oncology targets (prostate, leukemia, breast, lung), as well as several infectious diseases HIV, HCV, HPV, and the flu. Based on earlier validation for producing uncommonly robust T-Cell responses, we are optimistic for the data expected in 4Q13, but note multiple Phase II catalysts expected this year in HCV and leukemia."

Inovio Pharmaceuticals closed at $0.67 on Thursday.

Latest Ratings for INO

DateFirmActionFromTo
Mar 2015HC WainwrightInitiates Coverage onBuy
Jul 2014Aegis CapitalUpgradesHoldBuy
May 2014Stifel NicolausInitiates Coverage onBuy

View More Analyst Ratings for INO
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (INO)

Around the Web, We're Loving...